Acorda Therapeutics Inc.
ACOR
NGS
Sector: Healthcare
Industry: Biotechnology
0.55
USD
-0.05
(-7.70%)
Optionable: Yes Market Cap: 15 M 90-day average vol: 851,440
Previous close: 0.6 Open: 0.52 Bid: 0.5431 Ask: 0.5956
52 week range
0.26 1.24
Last updated: Friday 2nd June 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordFinancials
ACOR Income Statement
Annual
| Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 336 M | 401 M | 493 M | 520 M | 588 M | 471 M | 192 M | 153 M | 129 M | 119 M |
| Cost of sales | 57 M | 69 M | 75 M | 86 M | 89 M | 78 M | -7 M | -19 M | 4 M | -5 M |
| Gross operating profit | 270 M | 321 M | 400 M | 411 M | 476 M | 384 M | 166 M | 130 M | 91 M | 90 M |
| Selling Gen & administrative expense | 186 M | 202 M | 206 M | 235 M | 182 M | 172 M | 193 M | 153 M | 124 M | 94 M |
| Research & development expense | 54 M | 73 M | 149 M | 203 M | 166 M | 106 M | 60 M | 23 M | 10 M | 6 M |
| Operating income | 30 M | 46 M | 45 M | -27 M | 105 M | 93 M | -121 M | -87 M | -77 M | -42 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -2 M | -9 M | -10 M | 1 M | -338 M | -55 M | -136 M | 9 M | -2 M | 35 M |
| Pre-tax Income (EBT) | 29 M | 28 M | 19 M | -42 M | -252 M | 20 M | -274 M | -108 M | -109 M | -35 M |
| Income taxes | 12 M | 10 M | 8 M | -7 M | -29 M | -13 M | -1 M | -8 M | -5 M | 31 M |
| Net income from total operations | 16 M | 18 M | 11 M | -36 M | -223 M | 34 M | -273 M | -100 M | -104 M | -66 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 16 M | 18 M | 11 M | -35 M | -222 M | 34 M | -273 M | -100 M | -104 M | -66 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 16 M | 18 M | 11 M | -36 M | -223 M | 34 M | -273 M | -100 M | -104 M | -66 M |
| Depreciation | 10 M | 12 M | 18 M | 22 M | 23 M | 10 M | 33 M | 42 M | 34 M | 33 M |
| Amortization | 0 | 0 | 0 | 0 | 24 M | 2 M | 26 M | 31 M | 31 M | 31 M |
| Operating income before depreciation (EBITDA) | 38 M | 46 M | 50 M | -4 M | -209 M | 53 M | -218 M | -36 M | -45 M | 28 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 2.46 | 2.58 | 1.56 | -4.56 | -29.16 | 4.32 | -34.5 | -12.32 | -9.79 | -3.34 |
| Diluted EPS total | 2.34 | 2.52 | 1.5 | -4.56 | -29.16 | 4.26 | -34.5 | -12.32 | -9.79 | -3.34 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and starter sheets.
Get started today
Get started today